Drug Profile
Amiselimod - Mitsubishi Tanabe Pharma Corporation/Salix Pharmaceuticals
Alternative Names: MT-1303; SLX-G1018Latest Information Update: 17 Aug 2023
Price :
$50
*
At a glance
- Originator Mitsubishi Tanabe Pharma Corporation
- Developer Mitsubishi Tanabe Pharma Corporation; Salix Pharmaceuticals
- Class Anti-inflammatories; Antipsoriatics; Propylene glycols; Small molecules
- Mechanism of Action Immunosuppressants; Sphingosine-1-phosphate receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Ulcerative colitis
- Discontinued Autoimmune disorders; Crohn's disease; Inflammation; Inflammatory bowel diseases; Multiple sclerosis; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Plaque psoriasis; Systemic lupus erythematosus
Most Recent Events
- 17 Aug 2023 Discontinued - Phase-I for Multiple sclerosis in Japan (PO)
- 17 Aug 2023 Discontinued - Phase-II for Crohn's disease in Ukraine, Israel, France, Germany, Poland, Italy, Slovakia, Netherlands, Czech Republic, Hungary (PO)
- 17 Aug 2023 Discontinued - Phase-II for Multiple sclerosis in Ukraine, Turkey, Switzerland, Serbia, Russia, Canada, United Kingdom (PO)